Caribou Biosciences, Inc. (NASDAQ:CRBU) Stock Now Rated "Hold" by Wall Street Analysts

Key Points

• Analysts collectively rate Caribou Biosciences “Hold.” Among eight covering brokerages, ratings include one sell, four holds, two buys and one strong buy, with an average 12-month price target of $5.50.
• CRBU shares have fallen sharply, opening at $0.47 and trading near their 12-month low of $0.44, versus a high of $3.54. Institutional investors and hedge funds own 77.51% of the company.
• In its latest quarter, Caribou reported a smaller-than-expected loss of $0.24 per share but revenue of $1.50 million, below the $2.28 million consensus estimate. Analysts expect a full-year loss of approximately $1.07 per share.

Caribou Biosciences, Inc. (NASDAQ:CRBU - Get Free Report) has been given an average rating of "Hold" by the eight brokerages that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, four have given a hold rating, two have given a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $5.50.

CRBU has been the topic of a number of analyst reports. Weiss Ratings reissued a "sell (d-)" rating on shares of Caribou Biosciences in a research report on Friday, July 17th. Royal Bank Of Canada cut Caribou Biosciences from an "outperform" rating to a "sector perform" rating and set a $1.00 price objective for the company. in a report on Wednesday, October 7th. Bank of America cut their target price on Caribou Biosciences from $6.00 to $5.00 and set a "buy" rating for the company in a research report on Friday, August 14th. HC Wainwright downgraded Caribou Biosciences from a "buy" rating to a "neutral" rating in a research report on Thursday, October 8th. Finally, Leerink Partners reissued a "market perform" rating and set a $1.00 target price (down from $4.00) on shares of Caribou Biosciences in a report on Wednesday, October 7th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of CRBU. CTC Alternative Strategies Ltd. bought a new stake in Caribou Biosciences during the first quarter worth about $29,000. Westmount Partners LLC bought a new position in Caribou Biosciences in the 1st quarter valued at about $37,000. Next Capital Management LLC bought a new position in Caribou Biosciences in the 2nd quarter valued at about $35,000. The Manufacturers Life Insurance Company bought a new position in Caribou Biosciences in the 2nd quarter valued at about $41,000. Finally, Spark Investment Management LLC bought a new position in Caribou Biosciences in the 2nd quarter valued at about $42,000. Institutional investors and hedge funds own 77.51% of the company's stock.

Caribou Biosciences Stock Down 5.4%

Shares of NASDAQ:CRBU opened at $0.47 on Wednesday. Caribou Biosciences has a 12-month low of $0.44 and a 12-month high of $3.54. The company's 50 day moving average price is $1.37 and its two-hundred day moving average price is $1.71. The firm has a market cap of $50.39 million, a PE ratio of -0.44 and a beta of 2.31.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.24) earnings per share for the quarter, beating analysts' consensus estimates of ($0.32) by $0.08. The company had revenue of $1.50 million during the quarter, compared to the consensus estimate of $2.28 million. Caribou Biosciences had a negative net margin of 1,030.42% and a negative return on equity of 89.11%. On average, research analysts expect that Caribou Biosciences will post -1.07 EPS for the current year.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc is a clinical-stage biotechnology company developing genome-edited cell therapies for cancer and other serious diseases. The company uses its proprietary CRISPR-based chRDNA genome-editing platform to engineer immune cells, with an emphasis on allogeneic, or “off-the-shelf,” CAR-T therapies designed to target tumors without requiring cells to be collected from each individual patient.

Caribou's research and development programs have focused primarily on hematologic malignancies, including investigational CAR-T candidates directed at targets such as CD19 and BCMA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.